Asset Details
Do you wish to reserve the book?
Resistant hyponatraemia in a patient with follicular lymphoma and heart failure with reduced ejection fraction: a case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Resistant hyponatraemia in a patient with follicular lymphoma and heart failure with reduced ejection fraction: a case report
Do you wish to request the book?
Resistant hyponatraemia in a patient with follicular lymphoma and heart failure with reduced ejection fraction: a case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Resistant hyponatraemia in a patient with follicular lymphoma and heart failure with reduced ejection fraction: a case report
2021
Overview
Background
Hyponatraemia is a common problem in patients with heart failure. It can be difficult to treat, especially in the presence of the patient’s needs for diuresis and manipulation of the renin–angiotensin–aldosterone system (RAAS).
Case summary
This concerns a 74-year-old woman with follicular lymphoma and severe global left ventricular systolic dysfunction secondary to treatment with R-CHOP chemotherapy. She presented a difficult challenge in the management of her decompensated heart failure alongside hyponatraemia as low as 113 mmol/L. This was resistant to standard treatment. The resistance to usual measures necessitated treatment with Tolvaptan, a selective arginine vasopressin V2 inhibitor used to treat hyponatraemia in syndrome of inappropriate anti-diuretic hormone. This, along with a strict fluid restriction of 500 mL/day, resolved the patient’s hyponatraemia and enabled her discharge home on tolerated heart failure treatment. She has now remained stable for almost 12 months.
Discussion
The potential causes of hyponatraemia are discussed along with the role of Tolvaptan in its management.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.